Resilient Argenx stock surges on Phase 3 autoimmune myositis success

Argenx SE (ISIN NL0010832176) is seeing resilient stock momentum on August 17, 2026, as investors react to positive topline data from the Phase 3 ALKIVIA trial of its antibody-based therapy VYVGART Hytrulo in adults with autoimmune myositis, with the Nasdaq-listed shares showing a double-digit percentage gain intraday and a fresh reassessment of the company’s valuation backdrop.

Phase 3 ALKIVIA win lifts expectations

According to a detailed update on the Phase 3 ALKIVIA study published on August 17, 2026, VYVGART Hytrulo (efgartigimod) met the primary endpoint in adults with autoimmune myositis, delivering significant improvement in disease activity in a patient population that currently lacks approved targeted therapies. The Investing.com report on the autoimmune myositis trial describes how the ALKIVIA data underpin a broader commercial opportunity for efgartigimod across immunology indications beyond its initial myasthenia gravis label.

In one real-time biotech valuation overview dated August 17, 2026, Argenx is shown with a Nasdaq ARGX share price of $851.29 at the close of August 14, 2026 and a market capitalization of $53.24 billion, before the latest ALKIVIA news triggered a sharp upward move. The ad-hoc-news corporate analysis of Argenx highlights that the successful Phase 3 ALKIVIA outcome in autoimmune myositis effectively adds another data-supported revenue pillar to that valuation, inviting investors to reassess how much future income from expanded IgG-mediated disease coverage is embedded in the current share price.

Shares post double-digit percentage gains

On August 17, 2026, market snapshots for the Nasdaq listing show Argenx shares trading strongly higher intraday, with one quote indicating a price of $990.18 at 11:36:47 a.m. ET, representing a gain of 16.31% compared with the previous close of $851.29. The Nasdaq ARGX quote snapshot also reports that the stock opened the session at $927.33, suggesting that most of the move occurred in regular-hours trading as investors digested the ALKIVIA data.

A separate performance-focused note dated August 17, 2026 describes how Argenx shares climbed $126.60 during the most recent completed session to close at $977.89, representing a 14.9% one-day increase and signaling renewed optimism regarding the company’s clinical and commercial trajectory. An in-depth valuation review based on GF Value metrics compares that trading region around $982.35 with an intrinsic value estimate of $1,444.93, concluding that the shares still trade 32.0% below the modeled fair value even after the rally.

At the same time, European trading data for the primary Euronext Brussels listing show a closing price of EUR 753.80 as of a late-afternoon timestamp on August 17, 2026, reflecting more muted gains but still positive sentiment in the home market. The Brussels ARGX.BR quote summary indicates that, at that closing level, the stock added 0.69% on the day, underscoring that the largest price reaction is currently concentrated on the US Nasdaq venue where biotech growth investors are particularly active.

Valuation context after the rally

From a valuation perspective, the quick move from a prior close of $851.29 on August 14, 2026 to intraday trading around $990.18 on August 17, 2026 implies a gain of $138.89 per share over that window, equivalent to a 16.31% increase in market value for existing shareholders during a single session. The Nasdaq ARGX overview breaks out the previous close and intraday move, giving investors a clear view of how much of the ALKIVIA optimism is already reflected in the price.

Despite that sharp advance, valuation-focused coverage on August 17, 2026 still characterizes Argenx as trading at a discount to a modeled intrinsic value based on long-term cash flow potential from efgartigimod and other pipeline assets. One GF Value-based analysis references a share price region around $851.56 and an intrinsic value estimate of $1,444.93, translating into a 41.1% margin between that price and the suggested fair value; even when updated for the later price move toward $982.35, the discount remains at 32.0%, reinforcing the thesis that the ALKIVIA data have not fully closed the valuation gap.

That quantified valuation spread is particularly relevant for investors who follow biotech names through a lens that balances near-term clinical catalysts with longer-term revenue trajectories. A difference of $462.58 between a representative trading price of $982.35 and a modeled fair value of $1,444.93 on August 17, 2026 implies that the market is still assigning a substantial risk premium to execution around autoimmune myositis and other efgartigimod indications, even after the Phase 3 success reduced uncertainty on one front.

Analyst targets respond to clinical progress

The Phase 3 ALKIVIA data also appear to be influencing formal analyst price targets. A price-target change report dated August 17, 2026 notes that the average target price compiled across coverage has risen to $1,037.52 in one dataset, while a separate metrics table tied to the ALKIVIA news lists a higher average target of $1,229.81, both figures comfortably above recent trading regions.

Relative to the August 14, 2026 Nasdaq close of $851.29, an average target of $1,229.81 represents an upside room of $378.52 per share, or 44.5%, suggesting that professional coverage still anticipates meaningful further appreciation if Argenx delivers on its clinical and commercial roadmap. Even taking the intraday move to $990.18 on August 17, 2026 into account, the gap to that $1,229.81 average target remains $239.63, equal to a 24.2% potential increase from that intraday level, underscoring that the shares have rallied yet still sit below consensus fair-value markers.

In addition, a concise event summary dated August 17, 2026 highlights that Argenx’s stock on one European reporter’s screen was up 12.63% over the day in local currency terms following the ALKIVIA announcement, reinforcing the point that the clinical milestone is recognized as material on both sides of the Atlantic. The European trading-day recap pairs that percentage move with an explicit mention of the preliminary Phase 3 results, linking the price reaction directly to the autoimmune myositis news.

Guidance and earnings calendar signals

On the earnings side, a calendar overview tied to Argenx as of August 17, 2026 lists an upcoming Q3 2026 earnings release date of October 21, 2026, indicating when investors can expect more detailed guidance and financial figures that incorporate the early impact of recent clinical developments. The calendar and results overview combines that future reporting date with the ALKIVIA topline announcement, so investors can connect today’s clinical catalyst with the upcoming financial disclosures.

While detailed Q2 2026 revenue and earnings figures are not highlighted in the day-filtered snapshots underlying this overview, the visible calendar context makes clear that the Q3 2026 reporting window is now the next major opportunity for Argenx management to update the market on how the autoimmune myositis program and broader efgartigimod franchise are translating into top-line growth, margin trends and cash flow generation. Given that the ALKIVIA study met its primary endpoint ahead of that date, analysts are likely to refine their Q3 and full-year 2026 models to incorporate potential label expansion and earlier-than-expected uptake in autoimmune myositis once regulatory pathways are clarified.

VYVGART Hytrulo as a representative product

VYVGART Hytrulo, based on the Fc fragment-directed antibody efgartigimod, now stands as Argenx’s signature product in the autoimmune segment and serves as the primary driver behind the ALKIVIA readout. An FDA events and drug-alerts overview confirms that the company has already secured regulatory approval for VYVGART Hytrulo in myasthenia gravis, providing a commercial foundation for further indication expansion.

In autoimmune myositis, the Phase 3 ALKIVIA results released on August 17, 2026 show that VYVGART Hytrulo achieved clinically meaningful improvements in disease activity in adults, supporting a broader thesis that modulating pathogenic IgG antibodies through efgartigimod’s mechanism can deliver benefit across multiple IgG-driven conditions. The quantified patient-level improvements in the ALKIVIA dataset have not been fully broken out in the day-filtered summaries used here, but the success on the primary endpoint is enough to anchor a narrative in which VYVGART Hytrulo’s revenue potential is now tied not only to its already approved indication but also to a pipeline of additional autoimmune targets.

Shares and market context

For investors looking at the stock today, one of the most concrete reference points is the Nasdaq ARGX intraday quote of $990.18 as of August 17, 2026, 11:36:47 a.m. ET, which stands $138.89 above the previous close of $851.29 recorded at 4:00 p.m. ET on August 14, 2026 and marks a 16.31% gain in that timeframe. The intraday quote snapshot places that price within a session characterized by strong volume and a rapid repricing after the ALKIVIA announcement.

On Euronext Brussels, the ARGX.BR listing closed at EUR 753.80 on August 17, 2026, adding EUR 5.20 over the day and posting a 0.69% increase at a recorded timestamp of 5:35:06 p.m. local time. The Brussels quote data emphasize that while the percentage move in Europe is relatively modest compared with the double-digit Nasdaq gains, the direction is consistent; both venues reflect improved sentiment as markets digest the autoimmune myositis milestone and consider the still-significant gap between current prices and valuation models that place fair value well above $1,400 per share.

Go deeper

For a fuller picture of Argenx stock after the ALKIVIA autoimmune myositis success, additional deep-dives are available through the cited market-data and clinical-trial coverage, including prior analyses of the company’s IgG modulation platform and its evolving pipeline of autoimmune indications.

Read more

Additional background on Argenx, its immunology strategy and ongoing investor communication can be found through the company’s dedicated investor relations materials on its own website.

Company fact box

Company: Argenx SE
ISIN: NL0010832176
Ticker: ARGX
Exchange: Nasdaq, Euronext Brussels
Price (as of August 17, 2026, 11:36 a.m. ET): $990.18 USD
Market cap: $53.24 billion (as of August 14, 2026)
Sector / Industry: Biotechnology / Immunology
Index membership: Nasdaq composite
Next earnings date: October 21, 2026